Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands Extends Summer’s Eve Line On Ingredient Concerns

Executive Summary

Summer’s Eve helped drive the firm’s net sales up 3% to $257m in Prestige Brand’s latest quarter, but it also drove analysts’ questions on whether the brand will sustain growth despite health care advocates’ concerns about potential harmful effects from some ingredients common in feminine wipe products.

You may also be interested in...



OTC Evolution For Prestige Brands Combines Near- And Long-Term Strategies

BC, Goody's, Monistat marketer boosts domestic and international OTC revenues immediately with C.B. Fleet acquisition, looks ahead to manufacturing expansion.

NGO Seeks FDA Guidance On Colorant Use In Feminine Cleansers

Women's Voices for the Earth asks FDA to issue guidance regarding appropriate use of color additives in feminine personal-cleansing products following research indicating that certain colorants may pose health risks to women if the products are used as marketed.

Qualifying Suppliers For US Supplement Ingredient Identity Requirement Still An Option With Thorns

Failing to qualify suppliers “one of the more common citations” FDA inspectors find at supplement facilities, says ORA deputy director Michael Dutcher. “If you're not sort of reconfirming once in a while it could lead to a problem with your products that you weren't even expecting.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel